196 related articles for article (PubMed ID: 19443601)
1. Simple ratio analysis of 18F-fluorodopa uptake in striatal subregions separates patients with early Parkinson disease from healthy controls.
Jokinen P; Helenius H; Rauhala E; Brück A; Eskola O; Rinne JO
J Nucl Med; 2009 Jun; 50(6):893-9. PubMed ID: 19443601
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach.
Dhawan V; Ma Y; Pillai V; Spetsieris P; Chaly T; Belakhlef A; Margouleff C; Eidelberg D
J Nucl Med; 2002 Oct; 43(10):1324-30. PubMed ID: 12368370
[TBL] [Abstract][Full Text] [Related]
3. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
4. Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.
Nurmi E; Bergman J; Eskola O; Solin O; Vahlberg T; Sonninen P; Rinne JO
Synapse; 2003 Jun; 48(3):109-15. PubMed ID: 12645035
[TBL] [Abstract][Full Text] [Related]
5. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
[TBL] [Abstract][Full Text] [Related]
6. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
[TBL] [Abstract][Full Text] [Related]
7. Striatal subregional 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease: a two-year follow-up study.
Brück A; Aalto S; Nurmi E; Vahlberg T; Bergman J; Rinne JO
Mov Disord; 2006 Jul; 21(7):958-63. PubMed ID: 16550545
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
[TBL] [Abstract][Full Text] [Related]
9. Input functions for 6-[fluorine-18]fluorodopa quantitation in parkinsonism: comparative studies and clinical correlations.
Takikawa S; Dhawan V; Chaly T; Robeson W; Dahl R; Zanzi I; Mandel F; Spetsieris P; Eidelberg D
J Nucl Med; 1994 Jun; 35(6):955-63. PubMed ID: 8195882
[TBL] [Abstract][Full Text] [Related]
10. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Huang WS; Chiang YH; Lin JC; Chou YH; Cheng CY; Liu RS
J Nucl Med; 2003 Jul; 44(7):999-1005. PubMed ID: 12843212
[TBL] [Abstract][Full Text] [Related]
11. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.
Ishikawa T; Dhawan V; Kazumata K; Chaly T; Mandel F; Neumeyer J; Margouleff C; Babchyck B; Zanzi I; Eidelberg D
J Nucl Med; 1996 Nov; 37(11):1760-5. PubMed ID: 8917170
[TBL] [Abstract][Full Text] [Related]
12. Contralateral Posterior Putaminal
Zhou LL; Wang SY; Tian YY; Jiang T; Chen YC; Huang T; Zhang YD; Wang F
Curr Neurovasc Res; 2021; 18(4):465-469. PubMed ID: 34809545
[TBL] [Abstract][Full Text] [Related]
13. Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.
Gallagher CL; Oakes TR; Johnson SC; Chung MK; Holden JE; Bendlin BB; McLaren DG; Xu G; Nickles RJ; Pyzalski R; DeJesus O; Brown WD
Mov Disord; 2011 Mar; 26(4):614-20. PubMed ID: 21449008
[TBL] [Abstract][Full Text] [Related]
14. Combined FDOPA and 3OMFD PET studies in Parkinson's disease.
Dhawan V; Ishikawa T; Patlak C; Chaly T; Robeson W; Belakhlef A; Margouleff C; Mandel F; Eidelberg D
J Nucl Med; 1996 Feb; 37(2):209-16. PubMed ID: 8667046
[TBL] [Abstract][Full Text] [Related]
15. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging.
Ruottinen HM; Niinivirta M; Bergman J; Oikonen V; Solin O; Eskola O; Eronen E; Sonninen P; Rinne UK
Synapse; 2001 Apr; 40(1):19-26. PubMed ID: 11170218
[TBL] [Abstract][Full Text] [Related]
16. Corticostriatal covariance patterns of 6-[18F]fluoro-L-dopa and [18F]fluorodeoxyglucose PET in Parkinson's disease.
Kaasinen V; Maguire RP; Hundemer HP; Leenders KL
J Neurol; 2006 Mar; 253(3):340-8. PubMed ID: 16222426
[TBL] [Abstract][Full Text] [Related]
17. Striatal 6-[18F]fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction.
Ruottinen HM; Rinne JO; Oikonen VJ; Bergman JR; Haaparanta MT; Solin OH; Ruotsalainen UH; Rinne UK
Synapse; 1997 Dec; 27(4):336-46. PubMed ID: 9372556
[TBL] [Abstract][Full Text] [Related]
18. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
[TBL] [Abstract][Full Text] [Related]
19. Separating Parkinson's disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data.
Sawle GV; Playford ED; Burn DJ; Cunningham VJ; Brooks DJ
Arch Neurol; 1994 Mar; 51(3):237-43. PubMed ID: 8129633
[TBL] [Abstract][Full Text] [Related]
20. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
Stormezand GN; Chaves LT; Vállez García D; Doorduin J; De Jong BM; Leenders KL; Kremer BPH; Dierckx RAJO
Neuroimage Clin; 2020; 25():102161. PubMed ID: 31981888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]